The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma Summary CAR-T cell therapy for multiple myeloma significantly alters the patient’s existing T cell population. This Read More
Tags :Intensive / Critical Care Medicine
Downregulation of MICA/MICB improves cell persistence and clinical activity of
Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia Summary CAR T-cell therapy targeting NKG2D ligands (Read More
Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary
Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma Summary Plasmapheresis, a procedure that filters blood, has shown promise in overcoming resistance to anti-BCMA immunotherapies for multiple Read More
A novel chimeric antigen receptor T-cell therapy targeting CD84 for the treatment of acute myeloid and T-cell lymphoblastic leukemias Summary A novel CAR-T cell therapy targeting CD84 is showing promise for treating acute myeloid leukemia (Read More
Combining MCL-1 inhibition and CD37-directed chimeric antigen receptor T cells
Combining MCL-1 inhibition and CD37-directed chimeric antigen receptor T cells as an effective strategy to target T-cell lymphoma Summary Combining MCL-1 inhibition with CD37-directed CAR T-cell therapy shows promise for treating T-cell lymphoma. Read More
Endogenous T cell responses to fusion-derived neoantigens in pediatric acute
Endogenous T cell responses to fusion-derived neoantigens in pediatric acute leukemias Summary Pediatric acute leukemias, particularly those with fusion oncogenes, can generate unique neoantigens derived from the fusion point. Research has shown that the immune Read More
The European Conference on Infections in Leukaemia (ECIL-10) guidelines for
The European Conference on Infections in Leukaemia (ECIL-10) guidelines for COVID-19 should take convalescent plasma into proper consideration Summary The upcoming ECIL-10 guidelines for COVID-19 management in leukemia patients should thoroughly evaluate the potential benefits Read More